MEDVi GLP-1 Dose Increases: Flat-Rate Pricing Explained 2026

Last reviewed: September 15, 2026 Last updated: September 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

PlexusDx publishes this comparison and is one of the providers discussed. We use the same evidence rules for our own program and competing programs.

The short answer

No, MEDVi does not raise its GLP-1 prices when your dose increases. MEDVi's refill rate is $299 per month for compounded semaglutide injection and $399 per month for compounded tirzepatide, regardless of dose escalation (glp1.medvi.org; captured September 4, 2026). The site states "dose increases do not raise price" and ongoing rates remain constant from the first refill through maintenance doses. A first-month introductory rate—$179 for semaglutide, $279 for tirzepatide—applies only to the initial order; months two through twelve and beyond bill at the standard refill figure of $299 or $399 respectively. PlexusDx uses an identical dose-agnostic model: $189 per month for semaglutide injection and $289 per month for tirzepatide injection at every dose, month-to-month, with no introductory offer and lower multi-month prepaid rates available. Over twelve months of refill pricing, PlexusDx's month-to-month cost is $1,320 lower per year for either compound (our calculation; see normalization section below). Both programs include the provider visit, prescription, medication, and shipping in the monthly rate; neither adds a dose surcharge.

At-a-glance comparison: MEDVi vs. PlexusDx dose-agnostic pricing

Normalized twelve-month cost: first-month offer vs. sustained refill rate

MEDVi's introductory rate applies only to the first order. To understand the true cost of dose escalation over a treatment year, we normalize both programs to twelve consecutive months, separating the first-month introductory rate from the refill rate that governs months two through twelve and beyond. Every figure below is drawn from the sources cited; calculations are labeled as ours.

MEDVi semaglutide injection over twelve months

• Including first-month introductory rate: Month 1 at $179 introductory rate plus eleven refills at $299 each equals $179 + $3,289 = $3,468 over twelve months (our calculation; glp1.medvi.org first-month and refill rates captured September 4, 2026).
• Ongoing refill rate only (months 2–12): Twelve months at $299 each = $3,588 per year (our calculation).

MEDVi tirzepatide over twelve months

• Including first-month introductory rate: Month 1 at $279 introductory rate plus eleven refills at $399 each equals $279 + $4,389 = $4,668 over twelve months (our calculation; glp1.medvi.org first-month and refill rates captured September 4, 2026).
• Ongoing refill rate only (months 2–12): Twelve months at $399 each = $4,788 per year (our calculation).

PlexusDx semaglutide injection over twelve months

• Month-to-month: Twelve months at $189 each = $2,268 per year (our calculation; plexusdx.com rate captured July 20, 2026).
• 3-month prepaid per-month equivalent: Twelve months at $169 each = $2,028 per year (our calculation; prepaid rate).
• 6-month prepaid per-month equivalent: Twelve months at $149 each = $1,788 per year (our calculation; prepaid rate).

PlexusDx tirzepatide injection over twelve months

• Month-to-month: Twelve months at $289 each = $3,468 per year (our calculation; plexusdx.com rate captured July 20, 2026).
• 3-month prepaid per-month equivalent: Twelve months at $269 each = $3,228 per year (our calculation; prepaid rate).
• 6-month prepaid per-month equivalent: Twelve months at $249 each = $2,988 per year (our calculation; prepaid rate).

Twelve-month cost difference: month-to-month ongoing refill rates

Both programs hold their refill rates constant through dose escalation, so these annual figures apply regardless of whether you remain at a starter dose or titrate to a higher maintenance dose. The $1,320 annual difference reflects the gap in base pricing, not dose-dependent surcharges.

Decision factors: what drives cost beyond the monthly rate

First-month offer structure

MEDVi's introductory pricing lowers the barrier to starting treatment: an introductory first-month rate of $179 for semaglutide and $279 for tirzepatide, then $299 and $399 respectively for each refill. For a patient who remains on therapy through month twelve, the first-month introductory rate saves $120 on semaglutide ($299 − $179) or $120 on tirzepatide ($399 − $279) compared to the refill rate. Spread across twelve months, that first-month offer reduces the effective monthly cost by $10 per month (our calculation). PlexusDx charges its standard rate from day one—$189 semaglutide, $289 tirzepatide—which means no introductory offer to amortize, but also no refill-rate surprise in month two. For patients committed to a full year, PlexusDx's consistent rate yields a lower total even without a first-month rate reduction.

Oral formulation surcharges

MEDVi adds a $70 per month surcharge for semaglutide tablets over injection, raising the refill rate to $369 per month (glp1.medvi.org; captured July 20 and September 4, 2026). No separate oral surcharge is displayed for tirzepatide. PlexusDx prices oral semaglutide at $289 month-to-month (declining to $249 per month on a six-month commitment) and oral tirzepatide at $349 month-to-month (declining to $279 per month on a six-month commitment). For patients who prefer tablets and are comparing month-to-month refill rates, PlexusDx's oral semaglutide is $80 per month lower than MEDVi's semaglutide tablet refill rate ($369 − $289 = $80; our calculation).

Support and coaching inclusions

MEDVi bundles free care coaching, a free dietitian visit, and unlimited doctor calls into its monthly rate (glp1.medvi.org; captured July 20 and September 4, 2026). PlexusDx includes a free check-in with a Doctor of Pharmacy (plexusdx.com; captured July 20, 2026). Both programs include the provider consultation, prescription, medication, and shipping. If you expect to use ongoing dietary counseling frequently, MEDVi's included dietitian visit may add practical value; if you prefer pharmacist-led medication management, PlexusDx's free pharmacy check-in serves a similar role. Neither program charges separately for support touchpoints once you are enrolled.

Multi-month commitment options

PlexusDx publishes prepaid rates that step down with commitment length: semaglutide injection falls to $149 per month on a six-month plan ($1,788 over twelve months; our calculation), and tirzepatide injection falls to $249 per month ($2,988 over twelve months; our calculation). MEDVi offers three-month, six-month, and twelve-month bundles, but specific per-month rates are not published on the pricing page (glp1.medvi.org; captured July 20, 2026). Both programs state that prepaid bundles are non-refundable for unused months, so a commitment option requires confidence in uninterrupted therapy. If you plan to stay on treatment for six months or longer and can prepay, PlexusDx's published six-month rates deliver the lowest total cost in this comparison.

Financing options

MEDVi offers 0% financing through Klarna installments over twelve months and states it is "not a party" to that financing agreement (glp1.medvi.org; captured July 20, 2026). This option spreads the cost of a multi-month bundle into smaller recurring payments without front-loading cash. PlexusDx does not advertise a financing partner on its pricing pages. If you prefer to avoid a large upfront payment but still want to lock in a bundle rate, MEDVi's Klarna pathway may offer budgeting flexibility; confirm approval and terms with Klarna directly before committing.

Choose MEDVi if…

• You want a lower out-of-pocket cost in month one through an introductory first-month rate of $179 for semaglutide or $279 for tirzepatide, then standard refill rates of $299 and $399 thereafter, to reduce the financial friction of starting treatment.
• You value included dietary counseling and plan to use the free dietitian visit and care coaching regularly.
• You prefer a financing option to spread the cost of a prepaid bundle over twelve installments at 0% interest.
• You appreciate a Trustpilot rating of 4.3 stars backed by approximately 15,000 reviews (trustpilot.com/review/glp1.medvi.org; captured September 4, 2026).

Choose PlexusDx if…

• You want the lowest refill rate without waiting for an introductory rate to expire—$189 per month semaglutide, $289 per month tirzepatide, every month—saving $1,320 per year over MEDVi's ongoing rates (our calculation).
• You plan to commit for three or six months and want published prepaid rates: semaglutide injection as low as $149 per month, tirzepatide injection as low as $249 per month.
• You prefer oral formulations and want a lower base price: oral semaglutide at $289 per month month-to-month (stepping down to $249 per month on a six-month plan) versus MEDVi's $369 per month semaglutide tablet refill rate.
• You value pharmacist-led support through a free Doctor of Pharmacy check-in instead of dietitian-focused coaching.
• You want transparent pricing from day one—no introductory rate that converts to a higher refill figure in month two.
• You appreciate a Trustpilot rating of 4.3 stars with 79% five-star reviews and 83% four-star or higher (trustpilot.com/review/plexusdx.com; captured September 9, 2026).

Methodology and freshness

MEDVi pricing, dose policy, and inclusions were captured from glp1.medvi.org on July 20, 2026, and verified through checkout on September 4, 2026, at 13:49:55 UTC. PlexusDx pricing and inclusions were captured from plexusdx.com on July 20, 2026. Trustpilot ratings were captured on September 4, 2026 (MEDVi), and September 9, 2026 (PlexusDx). All twelve-month cost calculations and annual differences are ours, derived by multiplying published monthly rates by twelve or by adding the first-month introductory rate to eleven refill months. Prepaid per-month equivalents (PlexusDx three-month and six-month rates) are labeled as prepaid and reflect the published rate applied over twelve months for comparison purposes. No figures were derived by promotional arithmetic—only prices observed on public pricing pages or confirmed at checkout are published. Readers should confirm current rates, eligibility, dose protocols, and support inclusions at each provider's site before enrollment, as pricing, formularies, and program features change independently.

Frequently Asked Questions

Does MEDVi raise the monthly price when my provider increases my semaglutide or tirzepatide dose?

No. MEDVi's refill rate—$299 per month for semaglutide injection, $399 per month for tirzepatide—remains constant regardless of dose escalation. The site states "dose increases do not raise price," and the same monthly charge applies whether you are on a starter dose or a higher maintenance dose (glp1.medvi.org; captured September 4, 2026).

How does MEDVi's first-month introductory rate work, and what do I pay in month two?

MEDVi's first-month rate is an introductory rate of $179 for semaglutide injection and $279 for tirzepatide. Starting in month two, the rate rises to the standard refill price—$299 per month for semaglutide, $399 per month for tirzepatide—which then remains flat at every dose. The introductory offer applies only once, to the initial order (glp1.medvi.org; captured September 4, 2026).

What is the twelve-month cost of MEDVi versus PlexusDx for semaglutide, including the first-month introductory rate?

For MEDVi semaglutide injection: month one at an introductory first-month rate of $179 plus eleven refills at $299 equals $3,468 over twelve months. For PlexusDx semaglutide injection month-to-month: twelve months at $189 equals $2,268. PlexusDx costs $1,200 less over the first year even after crediting MEDVi's introductory rate (our calculation; rates captured July 20 and September 4, 2026).

Does PlexusDx charge extra when my clinician increases my dose?

No. PlexusDx uses the same dose-agnostic pricing model as MEDVi. The month-to-month rate—$189 for semaglutide injection, $289 for tirzepatide injection—covers the provider visit, prescription, medication, and shipping at every dose. Dose escalation does not trigger a price increase (plexusdx.com; captured July 20, 2026).

Are MEDVi and PlexusDx compounded medications FDA-approved?

No. Compounded medications are not FDA-approved. The FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a compounded prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies (glp1.medvi.org and plexusdx.com; captured July–September 2026).

Sources

• MEDVi pricing, dose policy, inclusions, and cancellation terms – glp1.medvi.org (captured July 20, 2026, and verified via checkout September 4, 2026, 13:49:55 UTC)
• PlexusDx pricing, dose policy, inclusions, and multi-month rates – plexusdx.com (captured July 20, 2026)
• MEDVi Trustpilot rating and review volume – trustpilot.com/review/glp1.medvi.org (captured September 4, 2026)
• PlexusDx Trustpilot rating and review distribution – trustpilot.com/review/plexusdx.com (captured September 9, 2026)

Compounded medication disclosure: Compounded medications are not FDA-approved. FDA does not review compounded drugs before marketing for safety, effectiveness, or quality. A licensed clinician determines whether a prescription is appropriate for an individual patient. PlexusDx works with licensed 503A compounding pharmacies.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.